Get the Stockscreener App
0.4109
10.27%
0.0352
Fibrobiologics Inc stock is traded at $0.4109, with a volume of 1.25M.
It is up +10.27% in the last 24 hours and up +82.43% over the past month.
FibroBiologics Inc a clinical-stage biotechnology company focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, or MS, degenerative disc disease, psoriasis, certain cancers, and potential human longevity applications including thymic involution reversal using a thymic organoid. Its product candidates are CYWC628, CYPS317, CYMS101 and CybroCell.
See More
Previous Close:
$0.3757
Open:
$0.39
24h Volume:
1.25M
Relative Volume:
0.69
Market Cap:
$27.84M
Revenue:
-
Net Income/Loss:
$-17.78M
P/E Ratio:
-0.7482
EPS:
-0.5492
Net Cash Flow:
$-10.52M
1W Performance:
+46.45%
1M Performance:
+82.43%
6M Performance:
-27.86%
1Y Performance:
-64.59%
1-Day Range:
$0.38
$0.439
1-Week Range:
$0.30
$0.4799
52-Week Range:
$0.2201
$1.53
Fibrobiologics Inc Stock (FBLG) Company Profile
Name
Fibrobiologics Inc
Sector
Industry
Phone
281-671-5150
Address
455 E. MEDICAL CENTER BLVD, HOUSTON
Compare FBLG vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBLG
Fibrobiologics Inc
|
0.4118 | 25.40M | 0 | -17.78M | -10.52M | -0.5492 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.70 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
762.45 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
721.77 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.03 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.37 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fibrobiologics Inc Stock (FBLG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-12-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-30-24 | Initiated | H.C. Wainwright | Buy |
| Sep-24-24 | Initiated | Maxim Group | Buy |
Fibrobiologics Inc Stock (FBLG) Latest News
FibroBiologics completes site onboarding for diabetic ulcer trial By Investing.com - Investing.com Nigeria
FibroBiologics (FBLG) CSO Khoja buys $11k in stock - Investing.com
FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers - Bitget
FibroBiologics Completes Site Onboarding for Phase 1/2 - GlobeNewswire
CEO Doubles Down on FibroBiologics With Bold Insider Stock Purchase - TipRanks
CFO’s Bold Insider Buy Sparks Fresh Buzz Around FibroBiologics Stock - TipRanks
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock By Investing.com - Investing.com Australia
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them - Benzinga
Davis Jason, FibroBiologics CFO, buys $28973 in FBLG stock - Investing.com
FibroBiologics (FBLG) CFO purchases 70,000 shares in open-market trade - Stock Titan
Insider Makes Bold New Bet on FibroBiologics Stock - TipRanks
FBLG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
FibroBiologics Jumps 22% On New Osteoporosis Patent, Stock Up - Nasdaq
Garcia Ruben A, FibroBiologics general counsel, buys $13k in FBLG - Investing.com
FibroBiologics receives patent for osteoporosis cell therapy - Investing.com
Garcia Ruben A, FibroBiologics general counsel, buys $13k in FBLG By Investing.com - Investing.com South Africa
FibroBiologics, Inc. announces issuance of U.S. patent covering fibroblast cell therapy for the treatment of osteoporosis - marketscreener.com
Fibrobiologics, Inc. Announces Issuance Of U.S. Patent Covering Fibroblast Cell Therapy For The Treatment Of Osteoporosis - TradingView
New fibroblast cell therapy patent targets osteoporosis - Stock Titan
FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis - Sahm
FBLG: Ready to Transition to Clinical-Stage Company - Smartkarma
FBLG Technical Analysis & Stock Price Forecast - Intellectia AI
FibroBiologics to Present at the BIO Investment & Growth Summit - Bitget
H.C. Wainwright cuts FibroBiologics stock price target to $4 By Investing.com - Investing.com Canada
H.C. Wainwright cuts FibroBiologics stock price target to $4 - Investing.com Nigeria
FibroBiologics Reports Full Year 2025 Financial Results and Provides Corporate Update - Bitget
FibroBiologics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
FibroBiologics (FBLG) expands fibroblast-based cell therapy pipeline - Stock Titan
FibroBiologics gets Nasdaq extension to meet listing rules - Investing.com Australia
FibroBiologics gets Nasdaq extension to meet listing rules By Investing.com - Investing.com South Africa
FibroBiologics Shareholders Approve Reverse Split, Warrant Issuances - TipRanks
FibroBiologics shareholders approve reverse stock split and warrant share issuances - Investing.com Nigeria
FibroBiologics (NASDAQ: FBLG) investors approve reverse split and warrant shares - Stock Titan
FibroBiologics Granted Extension by Nasdaq to Regain Compliance - Bitget
FBLG PE Ratio & Valuation, Is FBLG Overvalued - Intellectia AI
Weekly Recap: Is FibroBiologics Inc stock overvalued or fairly pricedJuly 2025 Technicals & Growth Focused Entry Point Reports - baoquankhu1.vn
Analysis Recap: Is FibroBiologics Inc. benefiting from interest rate changesJuly 2025 Earnings & Real-Time Market Sentiment Reports - mfd.ru
How FibroBiologics Inc. stock reacts to inflationary pressuresJuly 2025 Patterns & Advanced Swing Trade Entry Alerts - mfd.ru
Should I add FibroBiologics Inc. stock to my portfolio2025 Earnings Impact & AI Based Buy/Sell Signal Reports - mfd.ru
FBLG Should I Buy - Intellectia AI
Aug Drivers: Can Xenetic Biosciences Inc be recession proofTrade Performance Summary & Long-Term Safe Investment Plans - baoquankhu1.vn
What’s the fair value of FibroBiologics Inc. stockJuly 2025 Recap & Daily Profit Focused Screening - mfd.ru
FibroBiologics CEO Pete O’Heeron to Speak at A4LI's H-SPAN Summit on Longevity Science - Quiver Quantitative
Longevity policy summit taps FibroBiologics CEO for main stage talk - Stock Titan
Is FibroBiologics Inc. benefiting from interest rate changesJuly 2025 Trends & Technical Pattern Based Signals - mfd.ru
FibroBiologics Faces Nasdaq Delisting Review After Noncompliance - TipRanks
FibroBiologics Received Notice of Delisting - TradingView
FibroBiologics Secures Canadian Patent for Innovative Cachexia Treatment Using Fibroblast Cells - Quiver Quantitative
FibroBiologics Announces Issuance of Canadian Patent Covering Novel Fibroblast-Based Treatment for Cachexia - ChartMill
FibroBiologics (NASDAQ:FBLG) Shares Down 1.6% – What’s Next? - Defense World
Market Recap: Whats the fair value of FibroBiologics Inc stockSell Signal & Reliable Trade Execution Plans - baoquankhu1.vn
Fibrobiologics Inc Stock (FBLG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fibrobiologics Inc Stock (FBLG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 03 '26 |
Buy |
0.41 |
18,200 |
7,373 |
5,942,275 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 02 '26 |
Buy |
0.35 |
17,428 |
6,152 |
5,924,075 |
| O'HEERON PETE | CHIEF EXECUTIVE OFFICER |
Mar 04 '26 |
Buy |
0.38 |
15,872 |
6,006 |
5,958,147 |
| Davis Jason | Chief Financial Officer |
Mar 02 '26 |
Buy |
0.41 |
70,000 |
28,973 |
70,000 |
| GARCIA RUBEN A | General Counsel |
Feb 27 '26 |
Buy |
0.33 |
40,000 |
13,056 |
180,000 |
| GARCIA RUBEN A | General Counsel |
Dec 11 '25 |
Buy |
0.34 |
140,000 |
47,600 |
140,000 |
| Khoja Hamid | Chief Scientific Officer |
May 27 '25 |
Buy |
0.84 |
20,000 |
16,800 |
31,250 |
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):